AR122043A1 - Dosificación y administración del anticuerpo anti-ctla-4 activable - Google Patents

Dosificación y administración del anticuerpo anti-ctla-4 activable

Info

Publication number
AR122043A1
AR122043A1 ARP210101266A ARP210101266A AR122043A1 AR 122043 A1 AR122043 A1 AR 122043A1 AR P210101266 A ARP210101266 A AR P210101266A AR P210101266 A ARP210101266 A AR P210101266A AR 122043 A1 AR122043 A1 AR 122043A1
Authority
AR
Argentina
Prior art keywords
ctla
antibody
dosage
administration
activable anti
Prior art date
Application number
ARP210101266A
Other languages
English (en)
Spanish (es)
Inventor
Leonard P James
Michelle Brown
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR122043A1 publication Critical patent/AR122043A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ARP210101266A 2020-05-12 2021-05-10 Dosificación y administración del anticuerpo anti-ctla-4 activable AR122043A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063023850P 2020-05-12 2020-05-12

Publications (1)

Publication Number Publication Date
AR122043A1 true AR122043A1 (es) 2022-08-03

Family

ID=76197648

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101266A AR122043A1 (es) 2020-05-12 2021-05-10 Dosificación y administración del anticuerpo anti-ctla-4 activable

Country Status (13)

Country Link
US (1) US20230192856A1 (enExample)
EP (1) EP4149544A1 (enExample)
JP (2) JP2023526232A (enExample)
KR (1) KR20230009432A (enExample)
CN (1) CN115515633A (enExample)
AR (1) AR122043A1 (enExample)
AU (1) AU2021270513A1 (enExample)
BR (1) BR112022022713A2 (enExample)
CA (1) CA3178649A1 (enExample)
IL (1) IL298126A (enExample)
MX (1) MX2022014113A (enExample)
TW (1) TW202207982A (enExample)
WO (1) WO2021231346A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260048119A1 (en) * 2022-08-05 2026-02-19 Bristol-Myers Squibb Company Anti-ctla4 antibodies for treatment of kras mutant cancers

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100845354B1 (ko) * 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항－ｃｔｌａ－4 항체의 용도
US8449886B2 (en) * 2008-01-08 2013-05-28 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010042433A1 (en) * 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
US9119129B2 (en) * 2012-05-05 2015-08-25 Broadcom Corporation MAC header based traffic classification and methods for use therewith
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP2912063A1 (en) * 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
SMT201900242T1 (it) * 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
RS64268B1 (sr) * 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
EP3114144A1 (en) * 2014-03-05 2017-01-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
JP2017515859A (ja) * 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
WO2016100561A2 (en) * 2014-12-16 2016-06-23 Bristol-Myers Squibb Company Use of immune checkpoint inhibitors in central nervous systems neoplasms
WO2016127052A1 (en) * 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
US10196445B1 (en) * 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
HRP20201334T1 (hr) * 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
WO2016176503A1 (en) * 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
WO2016196389A1 (en) * 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
US11072657B2 (en) * 2015-11-18 2021-07-27 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
EP3408296A1 (en) * 2016-01-27 2018-12-05 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2017210631A1 (en) * 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
KR102976378B1 (ko) * 2016-06-03 2026-06-11 브리스톨-마이어스 스큅 컴퍼니 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
WO2018049042A1 (en) * 2016-09-07 2018-03-15 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancers by inhibiting estrogen signaling in myeloid-derived suppressor cells
KR102634093B1 (ko) * 2016-10-28 2024-02-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
CN110072890B (zh) * 2016-11-03 2022-11-29 百时美施贵宝公司 可活化的抗ctla-4抗体及其用途
IL307242B1 (en) * 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
WO2019036433A2 (en) * 2017-08-16 2019-02-21 Bristol-Myers Squibb Company ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION
EP3694884A1 (en) * 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
WO2019140150A1 (en) * 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
EP3774911A1 (en) * 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
US11554120B2 (en) * 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
JP2022505647A (ja) * 2018-10-23 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍の処置方法
MX2021005708A (es) * 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
WO2020198676A1 (en) * 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
KR20210146348A (ko) * 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
JP7720785B2 (ja) * 2019-04-18 2025-08-08 ブリストル－マイヤーズ スクイブ カンパニー 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
WO2021055994A1 (en) * 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
WO2021127554A1 (en) * 2019-12-19 2021-06-24 Bristol-Myers Squibb Company Combinations of dgk inhibitors and checkpoint antagonists
CN115210235A (zh) * 2020-01-27 2022-10-18 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
CN115151547A (zh) * 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
KR20240153583A (ko) * 2022-02-25 2024-10-23 브리스톨-마이어스 스큅 컴퍼니 결장직장암종에 대한 병용 요법
CN122459678A (zh) * 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法

Also Published As

Publication number Publication date
MX2022014113A (es) 2022-12-08
JP2026102780A (ja) 2026-06-23
WO2021231346A1 (en) 2021-11-18
TW202207982A (zh) 2022-03-01
IL298126A (en) 2023-01-01
AU2021270513A1 (en) 2023-01-19
US20230192856A1 (en) 2023-06-22
CA3178649A1 (en) 2021-11-18
JP2023526232A (ja) 2023-06-21
BR112022022713A2 (pt) 2023-03-28
CN115515633A (zh) 2022-12-23
EP4149544A1 (en) 2023-03-22
KR20230009432A (ko) 2023-01-17

Similar Documents

Publication Publication Date Title
DOP2022000137A (es) Compuesto de piridazinil-tiazolcarboxamida
DOP2023000107A (es) Compuesto de heteroarilcarboxamida
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
MY204641A (en) Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX392487B (es) Métodos y composiciones para dosificación en terapia celular adoptiva.
MX2015015735A (es) Regimenes de dosificacion de inmunoconjugado anti-receptor en folato 1 (folr1).
MX368507B (es) Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-ctla-4 en la manufactura de un medicamento para el tratamiento de cáncer.
CR20220322A (es) Formulaciones de anticuerpos anti-pd-l1
EA201992612A1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
MX2016004411A (es) Regimenes de dosificacion de inmunoconjugado anti-receptor 1 de folato (folr1).
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
MX2024005430A (es) Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau.
BR112022022713A2 (pt) Dosagem e administração de anticorpo anti-ctla-4 ativável
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина
EA202190504A1 (ru) Способы лечения псориаза

Legal Events

Date Code Title Description
FA Abandonment or withdrawal